BioLife Solutions (NASDAQ:BLFS) Sees Strong Trading Volume – Time to Buy?

Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) saw unusually-high trading volume on Thursday . Approximately 758,919 shares traded hands during trading, an increase of 19% from the previous session’s volume of 638,184 shares.The stock last traded at $31.2330 and had previously closed at $31.15.

BioLife Solutions News Summary

Here are the key news stories impacting BioLife Solutions this week:

• Positive Sentiment: HC Wainwright reiterated a Neutral rating and a $31 price target while forecasting modest earnings growth for BioLife Solutions through 2027, which suggests analysts still see some upside from current levels. HC Wainwright earnings estimates and rating for BioLife Solutions
• Neutral Sentiment: Repligen’s planned acquisition of BioLife Solutions is being framed as strategically positive for Repligen’s cell therapy business, and the deal could provide a clear exit value for BLFS shareholders if completed. Zacks article on Repligen buying BioLife Solutions
• Negative Sentiment: Maxim Group downgraded BioLife Solutions (BLFS) from strong-buy to hold, adding pressure on the stock and signaling less enthusiasm from analysts. Maxim Group downgrade coverage via Zacks
• Negative Sentiment: Kahn Swick & Foti said it is investigating the adequacy of the price and process in BioLife’s proposed sale to Repligen, raising the risk of shareholder litigation or a challenged deal process. BusinessWire investor alert on BioLife Solutions sale investigation
• Negative Sentiment: TD Cowen also downgraded BioLife Solutions (BLFS) to hold, reinforcing the cautious tone around the stock after the acquisition announcement. TD Cowen downgrade on BioLife Solutions

Analysts Set New Price Targets

Several brokerages have recently issued reports on BLFS. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioLife Solutions in a report on Friday, July 17th. Maxim Group downgraded BioLife Solutions from a “strong-buy” rating to a “hold” rating in a report on Wednesday. Zacks Research lowered BioLife Solutions from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 12th. William Blair set a $31.00 target price on BioLife Solutions in a report on Thursday. Finally, Wall Street Zen downgraded BioLife Solutions from a “buy” rating to a “hold” rating in a research report on Saturday. One investment analyst has rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, BioLife Solutions presently has an average rating of “Hold” and an average price target of $31.43.

BioLife Solutions Stock Performance

The stock’s fifty day simple moving average is $26.94 and its two-hundred day simple moving average is $23.55. The stock has a market capitalization of $1.46 billion, a P/E ratio of -374.70 and a beta of 1.94.

BioLife Solutions (NASDAQ:BLFS) last released its quarterly earnings results on Thursday, May 7th. The medical equipment provider reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.03. The firm had revenue of $27.50 million during the quarter, compared to the consensus estimate of $25.66 million. BioLife Solutions had a negative net margin of 2.80% and a positive return on equity of 1.81%. As a group, analysts expect that BioLife Solutions, Inc. will post 0.02 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, major shareholder Casdin Partners Master Fund, L sold 650,000 shares of the stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $23.70, for a total value of $15,405,000.00. Following the completion of the sale, the insider directly owned 4,757,165 shares in the company, valued at $112,744,810.50. This represents a 12.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold 1,200,000 shares of company stock valued at $28,125,000 in the last three months. Corporate insiders own 2.20% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Global Retirement Partners LLC acquired a new stake in shares of BioLife Solutions in the fourth quarter valued at about $30,000. Kemnay Advisory Services Inc. bought a new position in shares of BioLife Solutions during the fourth quarter worth about $35,000. State of Wyoming acquired a new position in shares of BioLife Solutions in the first quarter worth approximately $52,000. Quarry LP lifted its stake in shares of BioLife Solutions by 50.9% in the third quarter. Quarry LP now owns 2,113 shares of the medical equipment provider’s stock worth $54,000 after acquiring an additional 713 shares during the period. Finally, Hantz Financial Services Inc. boosted its holdings in BioLife Solutions by 42.4% in the fourth quarter. Hantz Financial Services Inc. now owns 2,673 shares of the medical equipment provider’s stock valued at $65,000 after acquiring an additional 796 shares during the last quarter. 93.24% of the stock is owned by institutional investors and hedge funds.

BioLife Solutions Company Profile

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.